Komori
Governance4512WAKAMOTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Corporate Governance Report 2026/04/01

The company has adopted a company-with-an-audit-and-supervisory-committee structure, established a Nomination and Compensation Committee, and disclosed the skills mix of its directors and executive officers. The body of the report does not describe any changes from the previous report.

Worth reading
85Important
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Number of directors9 directors (including 4 outside directors)
Committee4
Nomination and Compensation Committee (the proportion of outside committee members is 非開示)Risk Management CommitteeCompliance CommitteeSustainability Committee
Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
Number of directors9 directors (including 4 outside directors)
CommitteeNomination and Compensation Committee (the proportion of outside committee members is Not disclosed), Risk Management Committee, Compliance Committee, Sustainability Committee
Items this document does not state (5)
Number of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholderChanges this time

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company does not state any specific reasons for the changes.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Corporate Governance Report 2026/04/01 | WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) timely disclosure | Komori